The development of immune checkpoint inhibitors, such as anti- programmed death ligand 1 (PD-L1) antibodies, has led to preclinical studies in mTOR-driven diseases, such as LAM [87,88], and combinations with mTOR/PI3K inhibitors in cancer [89]. This evidence concerns the gene MTOR and cancer.